U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C14H19NO2
Molecular Weight 233.3062
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DEXMETHYLPHENIDATE

SMILES

COC(=O)[C@@H]([C@H]1CCCCN1)C2=CC=CC=C2

InChI

InChIKey=DUGOZIWVEXMGBE-CHWSQXEVSA-N
InChI=1S/C14H19NO2/c1-17-14(16)13(11-7-3-2-4-8-11)12-9-5-6-10-15-12/h2-4,7-8,12-13,15H,5-6,9-10H2,1H3/t12-,13-/m1/s1

HIDE SMILES / InChI
Molecular Formula C14H19NO2
Molecular Weight 233.3062
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Dexmethylphenidate is the dextrorotary form of methylphenidate. Dexmethylphenidate is marketed under the trade name Focalin. Focalin (dexmethylphenidate hydrochloride) is the d-threo-enantiomer of racemic methylphenidate hydrochloride, which is a 50/50 mixture of the d-threo and l-threoenantiomers. Focalin is a central nervous system (CNS) stimulant, available in three tablet strengths. Each tablet contains dexmethylphenidate hydrochloride 2.5, 5, or 10 mg for oral administration. Dexmethylphenidate is used as a treatment for ADHD, ideally in conjunction with psychological, educational, behavioral or other forms of treatment. Methylphenidate blocks dopamine uptake in central adrenergic neurons by blocking dopamine transport or carrier proteins. Methylphenidate acts at the brain stem arousal system and the cerebral cortex and causes increased sympathomimetic activity in the central nervous system. Methylphenidate is a catecholamine reuptake inhibitor that indirectly increases catecholaminergic neurotransmission by inhibiting the dopamine transporter (DAT) and norepinephrine transporter (NET), which are responsible for clearing catecholamines from the synapse, particularly in the striatum and meso-limbic system.

CNS Activity

CNS Active
4002
Curator's Comment: Dexmethylphenidate is a central nervous system (CNS) stimulant

Originator

Approval Year

2001
187
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8504
 161.0 nM [Ki]
Inhibitor
8504
 206.0 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
FOCALIN

Approved Use

Focalin XR is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients aged 6 years and older. The effectiveness of Focalin XR in the treatment of ADHD in patients aged 6 years and older was established in two placebo-controlled studies in patients meeting DSM-IV criteria for ADHD.

Launch Date

2001
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
22.13 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/14747426
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXMETHYLPHENIDATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
23.72 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/14747426
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXMETHYLPHENIDATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
10.7 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/28590363
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXMETHYLPHENIDATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
131.9 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/14747426
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXMETHYLPHENIDATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
120.9 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/14747426
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXMETHYLPHENIDATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
79.8 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/28590363
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXMETHYLPHENIDATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.81 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/14747426
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXMETHYLPHENIDATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
2.68 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/14747426
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXMETHYLPHENIDATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
3.3 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/28590363
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXMETHYLPHENIDATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
Doses

Doses

DosePopulationAdverse events​
40 mg single, oral
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Other AEs: Vomiting, Agitation...
Other AEs:
Vomiting
Agitation
Tremor
Hyperreflexia
Muscle twitching
Convulsions
Euphoria
Confusion
Hallucinations
Delirium
Sweating
Flushing
Headache
Hyperpyrexia
Tachycardia
Palpitations
Cardiac arrhythmias
Hypertension
Mydriasis
Mucosal dryness
Rhabdomyolysis
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
30 mg 1 times / day multiple, oral
Recommended
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Disc. AE: Twitching, Anorexia...
AEs leading to
discontinuation/dose reduction:
Twitching (1%)
Anorexia (1%)
Insomnia (1%)
Tachycardia (1%)
Insomnia (1.8%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Disc. AE: Cardiac disorders, Stroke...
Other AEs: Increased blood pressure, Heart rate increased...
AEs leading to
discontinuation/dose reduction:
Cardiac disorders (grade 3-5)
Stroke (grade 3-5)
Myocardial infarction (grade 3-5)
Seizures
Raynaud's phenomenon
Other AEs:
Increased blood pressure
Heart rate increased
Psychotic symptom (grade 3-5)
Psychotic symptom
Manic symptom
Aggression
Growth suppression
Priapism
Erection prolonged
Vascular disorders
Visual disturbance
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Disc. AE: Feeling jittery, Anorexia...
AEs leading to
discontinuation/dose reduction:
Feeling jittery (1.8%)
Anorexia (1.2%)
Anxiety (1.2%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
AEs

AEs

AESignificanceDosePopulation
Agitation
40 mg single, oral
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Cardiac arrhythmias
40 mg single, oral
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Confusion
40 mg single, oral
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Convulsions
40 mg single, oral
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Delirium
40 mg single, oral
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Euphoria
40 mg single, oral
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Flushing
40 mg single, oral
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Hallucinations
40 mg single, oral
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Headache
40 mg single, oral
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Hyperpyrexia
40 mg single, oral
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Hyperreflexia
40 mg single, oral
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Hypertension
40 mg single, oral
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Mucosal dryness
40 mg single, oral
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Muscle twitching
40 mg single, oral
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Mydriasis
40 mg single, oral
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Palpitations
40 mg single, oral
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Rhabdomyolysis
40 mg single, oral
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Sweating
40 mg single, oral
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Tachycardia
40 mg single, oral
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Tremor
40 mg single, oral
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Vomiting
40 mg single, oral
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Anorexia 1%
Disc. AE
30 mg 1 times / day multiple, oral
Recommended
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Insomnia 1%
Disc. AE
30 mg 1 times / day multiple, oral
Recommended
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Tachycardia 1%
Disc. AE
30 mg 1 times / day multiple, oral
Recommended
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Twitching 1%
Disc. AE
30 mg 1 times / day multiple, oral
Recommended
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Insomnia 1.8%
Disc. AE
30 mg 1 times / day multiple, oral
Recommended
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Aggression
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Erection prolonged
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Growth suppression
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Heart rate increased
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Increased blood pressure
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Manic symptom
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Priapism
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Psychotic symptom
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Vascular disorders
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Visual disturbance
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Raynaud's phenomenon Disc. AE
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Seizures Disc. AE
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Psychotic symptom grade 3-5
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Cardiac disorders grade 3-5
Disc. AE
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Myocardial infarction grade 3-5
Disc. AE
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Stroke grade 3-5
Disc. AE
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Anorexia 1.2%
Disc. AE
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Anxiety 1.2%
Disc. AE
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Feeling jittery 1.8%
Disc. AE
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
2438
inhibitor
2507

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A2
2153

CYP2C8
1057

CYP2C19
2057

CYP2E1
1060

CYP3A
227
esterase
74

CES2
33

P-gp
2052
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP1A2
2333
 no
CYP2C19
2141
 no
CYP2C8
1117
 no
CYP2C9
2497
 no
CYP2E1
1146
 no
CYP3A
317
 no
CYP2D6
2546
 no
no (co-administration study)
Comment: Clinically, methylphenidate coadministration did not increase plasma concentrations of the CYP2D6 substrate desipramine.
Page: 11.0
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CES2
33
 no
P-gp
2052
 weak
esterase
74
 yes
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:51860
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:51860
ZINC
ZINC000000896711
http://zinc15.docking.org/substances/ZINC000000896711
PubMed

PubMed

TitleDatePubMed
[Prescribing ritalin in combined modality management of hyperactivity with attention deficit].
2001 Sep-Oct
A single-dose, two-way crossover, bioequivalence study of dexmethylphenidate HCl with and without food in healthy subjects.
2004 Feb
Efficacy of two once-daily methylphenidate formulations compared across dose levels at different times of the day: preliminary indications from a secondary analysis of the COMACS study data.
2004 Sep 30
Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.
2008 May
Psychopharmacology of ADHD in pediatrics: current advances and issues.
2009
Once-daily medications for the pharmacological management of ADHD in adults.
2009 Apr
Long-term effectiveness and safety of dexmethylphenidate extended-release capsules in adult ADHD.
2009 Mar
Efficacy of dexmethylphenidate for the treatment of fatigue after cancer chemotherapy: a randomized clinical trial.
2009 Nov
Patents

Patents

JP2009526755A
475
JP2011510954A
147

Sample Use Guides

In Vivo Use Guide
Focalin (Dexmethylphenidate) is administered twice daily, at least 4 hours apart. Focalin may be administered with or without food. The recommended starting dose of Focalin for patients who are not currently taking racemic methylphenidate, or for patients who are on stimulants other than methylphenidate, is 5 mg/day (2.5 mg twice daily). Dosage may be adjusted in 2.5 to 5 mg increments to a maximum of 20 mg/day (10 mg twice daily). In general, dosage adjustments may proceed at approximately weekly intervals.
Route of Administration: Oral
In Vitro Use Guide
Dexmethylphenidate inhibition [3H]dopamine uptake at human DAT expressed in mouse N2A cells with IC50 156 nM.
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:07:24 GMT 2025
Edited
by admin
on Mon Mar 31 18:07:24 GMT 2025
Record UNII
M32RH9MFGP
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DEXMETHYLPHENIDATE
INN   VANDF   WHO-DD  
INN  
Official Name English
METHYLPHENIDATE D-THREO-FORM
MI  
Preferred Name English
Dexmethylphenidate [WHO-DD]
Common Name English
2-PIPERIDINEACETIC ACID, .ALPHA.-PHENYL-, METHYL ESTER, (.ALPHA.R,2R)-
Common Name English
METHYLPHENIDATE D-THREO-FORM [MI]
Common Name English
dexmethylphenidate [INN]
Common Name English
DEXMETHYLPHENIDATE [VANDF]
Common Name English
METHYL (2R)-PHENYL((2R)-PIPERIDIN-2-YL)ACETATE
Systematic Name English
Classification Tree Code System Code
WHO-VATC QN06BA11
Created by admin on Mon Mar 31 18:07:24 GMT 2025 , Edited by admin on Mon Mar 31 18:07:24 GMT 2025
NDF-RT N0000175729
Created by admin on Mon Mar 31 18:07:24 GMT 2025 , Edited by admin on Mon Mar 31 18:07:24 GMT 2025
NCI_THESAURUS C47795
Created by admin on Mon Mar 31 18:07:24 GMT 2025 , Edited by admin on Mon Mar 31 18:07:24 GMT 2025
WHO-ATC N06BA11
Created by admin on Mon Mar 31 18:07:24 GMT 2025 , Edited by admin on Mon Mar 31 18:07:24 GMT 2025
LIVERTOX 291
Created by admin on Mon Mar 31 18:07:24 GMT 2025 , Edited by admin on Mon Mar 31 18:07:24 GMT 2025
NDF-RT N0000175739
Created by admin on Mon Mar 31 18:07:24 GMT 2025 , Edited by admin on Mon Mar 31 18:07:24 GMT 2025
Code System Code Type Description
EVMPD
SUB30294
Created by admin on Mon Mar 31 18:07:24 GMT 2025 , Edited by admin on Mon Mar 31 18:07:24 GMT 2025
PRIMARY
ChEMBL
CHEMBL827
Created by admin on Mon Mar 31 18:07:24 GMT 2025 , Edited by admin on Mon Mar 31 18:07:24 GMT 2025
PRIMARY
WIKIPEDIA
DEXMETHYLPHENIDATE
Created by admin on Mon Mar 31 18:07:24 GMT 2025 , Edited by admin on Mon Mar 31 18:07:24 GMT 2025
PRIMARY
MERCK INDEX
m7453
Created by admin on Mon Mar 31 18:07:24 GMT 2025 , Edited by admin on Mon Mar 31 18:07:24 GMT 2025
PRIMARY Merck Index
CAS
40431-64-9
Created by admin on Mon Mar 31 18:07:24 GMT 2025 , Edited by admin on Mon Mar 31 18:07:24 GMT 2025
PRIMARY
IUPHAR
7554
Created by admin on Mon Mar 31 18:07:24 GMT 2025 , Edited by admin on Mon Mar 31 18:07:24 GMT 2025
PRIMARY
RXCUI
352372
Created by admin on Mon Mar 31 18:07:24 GMT 2025 , Edited by admin on Mon Mar 31 18:07:24 GMT 2025
PRIMARY RxNorm
PUBCHEM
154101
Created by admin on Mon Mar 31 18:07:24 GMT 2025 , Edited by admin on Mon Mar 31 18:07:24 GMT 2025
PRIMARY
LACTMED
Dexmethylphenidate
Created by admin on Mon Mar 31 18:07:24 GMT 2025 , Edited by admin on Mon Mar 31 18:07:24 GMT 2025
PRIMARY
SMS_ID
100000092743
Created by admin on Mon Mar 31 18:07:24 GMT 2025 , Edited by admin on Mon Mar 31 18:07:24 GMT 2025
PRIMARY
CHEBI
51860
Created by admin on Mon Mar 31 18:07:24 GMT 2025 , Edited by admin on Mon Mar 31 18:07:24 GMT 2025
PRIMARY
DRUG BANK
DB06701
Created by admin on Mon Mar 31 18:07:24 GMT 2025 , Edited by admin on Mon Mar 31 18:07:24 GMT 2025
PRIMARY
EPA CompTox
DTXSID70893769
Created by admin on Mon Mar 31 18:07:24 GMT 2025 , Edited by admin on Mon Mar 31 18:07:24 GMT 2025
PRIMARY
DRUG CENTRAL
836
Created by admin on Mon Mar 31 18:07:24 GMT 2025 , Edited by admin on Mon Mar 31 18:07:24 GMT 2025
PRIMARY
NCI_THESAURUS
C26642
Created by admin on Mon Mar 31 18:07:24 GMT 2025 , Edited by admin on Mon Mar 31 18:07:24 GMT 2025
PRIMARY
INN
8289
Created by admin on Mon Mar 31 18:07:24 GMT 2025 , Edited by admin on Mon Mar 31 18:07:24 GMT 2025
PRIMARY
DAILYMED
M32RH9MFGP
Created by admin on Mon Mar 31 18:07:24 GMT 2025 , Edited by admin on Mon Mar 31 18:07:24 GMT 2025
PRIMARY
FDA UNII
M32RH9MFGP
Created by admin on Mon Mar 31 18:07:24 GMT 2025 , Edited by admin on Mon Mar 31 18:07:24 GMT 2025
PRIMARY
Related Record Type Details
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
SODIUM-DEPENDENT DOPAMINE TRANSPORTER
TARGET -> INHIBITOR
Structure of DEXMETHYLPHENIDATE HYDROCHLORIDE
SALT/SOLVATE -> PARENT
Related Record Type Details
Structure of SERDEXMETHYLPHENIDATE
PRODRUG -> METABOLITE ACTIVE
Related Record Type Details
Structure of DEXMETHYLPHENIDATE
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Tmax PHARMACOKINETIC
Structure of DEXMETHYLPHENIDATE
following oral administration of serdexmethylphenidate single moiety alone
PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC
Structure of DEXMETHYLPHENIDATE
INTRAVENOUS ADMINISTRATION
PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC
Structure of DEXMETHYLPHENIDATE
IN HEALTHY ADULT SUBJECTS
PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966